LLY

Eli Lilly andB

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$1,360.00

+15.3% vs current

Most likely

Base case

50%

Probability

Target price

$1,265.00

+7.3% vs current

B-

Bear case

20%

Probability

Target price

$1,085.00

-8.0% vs current

AI sentiment snapshot

Latest data as of 2026-06-29

AI commentary

The deterministic prior is positive, recent June 2026 coverage is broadly supportive, and Lilly shares were being discussed as a market leader late in the month. Still, the most decision-relevant verified evidence remains the April 30, 2026 company 8-K rather than a newer primary-source operating update, and the packet lacks strong post-print analyst-revision, options, short-interest, and social-coverage depth. That keeps sentiment constructive but better framed as high-quality monitoring than as a new high-conviction chase setup.

RankAlpha Sentiment Codex - 2026-06-29

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-07-30catalystRaised 2026 guidance keeps near-term execution in focusMedium impact

Lilly's April 30, 2026 earnings 8-K reported Q1 revenue up 56% to $19.8 billion, non-GAAP EPS up 156% to $8.55, and increased full-year 2026 revenue guidance to $82.0 billion-$85.0 billion with non-GAAP EPS guidance of $35.50-$37.00. The setup stays favorable if obesity and cardiometabolic volume remains strong enough to offset lower realized prices on Mounjaro and Zepbound. [#SEC-8K-2026-04-30]

2026-12-07eventDecember 7, 2026 investment meeting is the clearest dated forward checkpointMedium impact

Lilly's April 30, 2026 8-K said the company plans an Investment Community Meeting for December 7, 2026. For a high-coverage biopharma name, that is the cleanest scheduled company event for management to reinforce or refine the obesity-franchise trajectory, pipeline pacing, and capital-allocation priorities. [#SEC-8K-2026-04-30]

2026-12-31catalystFoundayo launch and broader cardiometabolic pipeline progress support runwayHigh impact

The April 30, 2026 filing highlighted U.S. FDA approval of Foundayo (orforglipron) for obesity or overweight with weight-related medical problems, plus positive Phase 3 updates for Foundayo in type 2 diabetes and retatrutide in type 2 diabetes. That extends Lilly's growth runway beyond current injectable demand, but reimbursement, launch execution, and pricing durability still need to prove out. [#SEC-8K-2026-04-30]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-29 • Updated nightlySource: Internal modelMethodology